Press Releases May 4, 2026 04:30 PM

Cabot Corporation Board Increases Dividend

Cabot Corporation Announces 5% Increase in Quarterly Dividend Reflecting Strong Financial Position

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
CBT

Cabot Corporation's Board of Directors declared a 5% increase in its quarterly dividend to $0.4725 per share, payable June 12, 2026. The raise highlights confidence in the company's strong cash flow, liquidity, and earnings durability, while maintaining investment capacity and a flexible balance sheet.

Cabot Corporation Board Increases Dividend
CBT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Dividend increased by 5%, from $0.45 to $0.4725 per share, annualized to $1.89.
  • Board cites strong cash flow generation, robust liquidity, and durable earnings as reasons for the increase.
  • Cabot remains committed to balancing shareholder returns with continued investment in growth.

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- On May 1, 2026, the Board of Directors of Cabot Corporation (NYSE: CBT) declared a quarterly dividend of $0.4725 per share, an increase of 5% compared to the current quarterly dividend of $0.45 per share, payable on all outstanding shares of the Corporation’s common stock. The dividend is payable on June 12, 2026, to stockholders of record of such common stock at the close of business on May 29, 2026.

“Today’s dividend increase reflects the Board’s confidence in Cabot’s strong cash flow generation, robust liquidity position, and the durability of our earnings,” said Sean Keohane, President and Chief Executive Officer of Cabot Corporation. “Increasing the dividend by 5% is a clear demonstration of our commitment to returning cash to shareholders, consistent with our capital allocation framework. At the same time, Cabot remains well positioned to continue investing in growth while maintaining a strong and flexible balance sheet.”

On an annualized basis, the new dividend rate will be $1.89 per share versus $1.80 per share, previously.

About Cabot Corporation
Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading provider of reinforcing carbons, specialty carbons, battery materials, engineered elastomer composites, inkjet colorants, masterbatches and conductive compounds, fumed metal oxides and aerogel. For more information on Cabot, please visit the company’s website at cabotcorp.com. The Company regularly posts important information on its website and encourages investors and potential investors to consult the Cabot website regularly.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in the press release regarding Cabot's business that are not historical facts, including our strong cash flow generation, robust liquidity position and the durability of our earnings, are forward looking statements that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025.


Risks

  • Forward-looking statements involve risks such as market volatility and operational uncertainties that could impact cash flow and earnings.
  • Potential macroeconomic shifts could affect demand for specialty chemicals and materials produced by Cabot Corporation.
  • Uncertainties in supply chain or raw material costs may impact the company's financial performance.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026